Immunotherapy trial for advanced solid tumors and head/neck cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests CHS-114, a medicine designed to help the immune system fight advanced cancers. It is for adults whose cancer has continued growing or returned after standard treatments, and it checks safety and early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need an advanced solid tumor, or (for the head-and-neck arms) advanced or recurrent head/neck cancer that is not curable by surgery or radiation.
- Your cancer must have at least one measurable spot on scans that can be tracked; previously treated spots must show clear growth again.
- You must have had enough time pass since your last cancer treatment (timing depends on the drug).
- You need lab and heart function that are safe for study treatment (blood counts, kidney/liver labs, and heart pumping function).
- You must be able and willing to use birth control during treatment and for a period after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.